Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TNXP stock has decreased by 71.4% and is now trading at $0.2379. View which stocks have been most impacted by COVID-19.
Full Answer
Why did Tonix Pharmaceuticals shares crash 28% lower on Monday?
Aug 01, 2021 · Yes, but it's looking like a long shot. Tonix Pharmaceuticals ( TNXP -3.53% ) investors are having a bad week. Hot off the heels of a …
When is Tonix Pharmaceuticals'next quarterly earnings announcement?
Jul 26, 2021 · What happened Shares of Tonix Pharmaceuticals ( TNXP -1.10% ) were crashing 28.3% lower as of 10:24 a.m. EDT on Monday. The big decline came after Tonix announced on Friday following the market...
Where can I buy Tonix Pharmaceuticals (TNXP) stock?
Apr 03, 2022 · If we substitute the values, we will be able to find the R-value as follows. R = 100 x [ (0.24/30000) 1/10 - 1] = -69.08 %. The (above) calculated return corresponds to the past 10-year history of Tonix Pharmaceuticals Holding Corp (TNXP). If you want to know the returns for the ongoing year (2022) visit the, 2022 performance report of TNXP stock.
What are analysts'price targets for Tonix Pharmaceuticals'stock?
Jul 27, 2018 · Tonix crashes on PhIII PTSD failure, sending stock to the gutter Brittany Meiling After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is...
Why did Tonix Pharmaceuticals stock go down?
The big decline came after Tonix announced on Friday following the market close that it is halting enrollment in a late-stage clinical study evaluating TNX-102 SL in treating fibromyalgia.Jul 26, 2021
Is tonix Pharmaceuticals a good stock to buy?
Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Why was tonix stock so high?
What happened. A big regulatory win was reaping huge prizes for Tonix Pharmaceuticals ( TNXP 0.17% ) on Thursday. Following a new nod from the Food and Drug Administration (FDA) for one of its leading pipeline drugs, the biotech's shares went on a quick trip skyward, rising 33% in price on the day.Mar 3, 2022
Will tonix Pharmaceuticals stock rise?
The Wall Street analyst predicted that TONIX PHARMACEUTICALS HOLDING's share price could reach $0.60 by Apr 18, 2023. The average TONIX PHARMACEUTICALS HOLDING stock price prediction forecasts a potential upside of 240.91% from the current TNXP share price of $0.18.
Will tonix reverse split?
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.Oct 31, 2019
Will TXMD stock go up?
and has now fallen 5 days in a row. During the day the stock fluctuated 8.91% from a day low at $0.25 to a day high of $0.28....Predicted Opening Price for TherapeuticsMD Inc of Thursday, April 21, 2022.Fair opening price April 21, 2022Current price$0.26$0.26 (Undervalued)
Where is tonix Pharmaceuticals located?
Chatham, New jerseyTonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
How high does IDEX go?
IDEX stock hit a 2022 high of $1.44 in early January and a low of $0.87 later in the same month. In 2021 its stock price ranged from 88 cents to $5.53. In an interview with Capital.com, Vinod Jain, senior analyst at Aite-Novarica Group, said “the stock could see more volatility due to its current price point”.Mar 22, 2022
Is Tonix Pharmaceuticals a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock.
What stocks does MarketBeat like better than Tonix Pharmaceuticals?
Wall Street analysts have given Tonix Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tonix Pharmaceuticals wasn't one of them.
Are investors shorting Tonix Pharmaceuticals?
Tonix Pharmaceuticals saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 13,920,000 shares, a decline of 12.8% from the July 29th total of 15,960,000 shares.
When is Tonix Pharmaceuticals' next earnings date?
Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for Tonix Pharmaceuticals.
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Sunday, August, 8th. The company reported ($0.07) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.07).#N#View Tonix Pharmaceuticals' earnings history.
How has Tonix Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?
Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNXP shares have decreased by 15.0% and is now trading at $0.7062.#N#View which stocks have been most impacted by COVID-19.
When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?
Tonix Pharmaceuticals shares reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018.
The company is stopping enrollment in a late-stage study for its lead pipeline candidate
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Key Points
Tonix won't enroll any additional patients in a late-stage study of TNX-102 SL in treating fibromyalgia.
What happened
Shares of Tonix Pharmaceuticals ( NASDAQ:TNXP) were crashing 28.3% lower as of 10:24 a.m. EDT on Monday. The big decline came after Tonix announced on Friday following the market close that it is halting enrollment in a late-stage clinical study evaluating TNX-102 SL in treating fibromyalgia.
So what
Tonix made the decision to stop enrollment in its late-stage study of TNX-102 SL after the study's Independent Data Monitoring Committee (IDMC) completed an interim analysis.
Now what
What's next for the biotech company? Tonix isn't throwing in the towel on TNX-102 SL in fibromyalgia yet. The company plans to move forward with its late-stage study targeting fibromyalgia with the patients who are already enrolled.
1 TNXP Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Tonix Pharmaceuticals Holding Corp (TNXP) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Tonix Pharmaceuticals Holding Corp (TNXP) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Tonix Pharmaceuticals Holding Corp (TNXP) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Tonix Pharmaceuticals Holding Corp (TNXP) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
Brittany Meiling
After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock Friday morning.
Luca Issi
Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons, and M&A since 2013.
Amber Tong
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Kyle Blankenship
Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement factor inhibitor drug. Apellis, though, always had its eyes on bigger fish, but a first glimpse at pivotal data for a major indication has muddied the waters.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
Zachary Brennan
Overshadowed by President Biden’s vaccine mandate announcement, the administration earlier in the day released its top priorities for drug pricing reforms making their way through Congress.
John Carroll
One of Paul Hudson’s picks for Sanofi’s pipeline has gone down in defeat in a Phase III trial.
